Back to rankings
Goodwin

Goodwin

More information

United States • Finance

4

Structured finance: derivatives and structured products

The derivatives offering at Goodwin spans equity and debt capital markets transactions. The group is jointly led by Edwin O’Connor and John Servidio in New York, alongside James Barri in Boston. O’Connor’s recent caseload includes capped call transactions, while Servidio is also active in this area, often representing issuers and underwriters. Barri frequently represents investment banks as underwriters in public convertible note offerings. The team is engaged in derivatives transactions spanning the energy, life sciences, investment management, and financial services industries.
Legal 500 Editorial commentary

Accolades

Client satisfaction: Lawyer & team quality

Testimonials

Collated independently by Legal 500 research team.

  • ‘Goodwin has carved a niche where they are able to match the incumbent leaders in the equity derivatives space at much lower cost.’

  • ‘John Servidio has been the primary contact and combines a practical approach to transactions with solid knowledge of market and legal developments.’

Key clients

  • The Chemours Company
  • Pennymac Financial Services, Inc.
  • AvalonBay Communities
  • Tripadvisor, Inc.
  • Boston Properties
  • Medical Properties Trust
  • Rocket Lab USA, Inc.
  • Agilent Technologies
  • UDR, Inc.
  • Wayfair

Work highlights

Counsel to a syndicate of investment banks acting as initial purchasers at the closing of a Rule 144A offering by a subsidiary of Digital Realty Trust, Inc., of a $1.15 billion principal amount of its 1.875% Exchangeable Senior Notes due 2029, including $150 million of notes issued pursuant to the full exercise by the initial purchasers of an option to purchase additional notes.
Represented Boston Properties Limited Partnership, the operating partnership of BXP, Inc., in its upsized Rule 144A offering of a $1.0 billion aggregate principal amount of 2.00% Exchangeable Senior Notes due 2030, which included $150 million of notes issued pursuant to the full exercise of the initial purchasers’ option to purchase additional notes.
Represented BridgeBio Pharma, Inc. in its Rule 144A offering of a $575 million aggregate principal amount of 1.75% Convertible Senior Notes due 2031, which included the full exercise of the initial purchasers’ option to purchase an additional $75 million of notes.
Practice head

Edwin O’Connor; James Barri; John Servidio

Comparative Guides